Application 209279

Type
NDA
Sponsor
ACTELION PHARMS

Application Products#

Product, Drug, Ingredient table
ProductDrugIngredientFormStrengthReference drugReference standard
001TRACLEERBOSENTANTABLET, FOR SUSPENSION;ORAL32MGYesYes

NDC Listings For This Application#

NDC, Name, Nonproprietary name table
NDCNameNonproprietary nameLabelerMarketing categoryStatus
66215-103TracleerbosentanActelion Pharmaceuticals US, Inc.NDACurrent
66215-103TracleerbosentanActelion Pharmaceuticals US, Inc.NDACurrent
66215-103TracleerbosentanActelion Pharmaceuticals US, Inc.NDACurrent
66215-103TracleerbosentanActelion Pharmaceuticals US, Inc.NDACurrent
66215-103TracleerbosentanActelion Pharmaceuticals US, Inc.NDACurrent
66215-103TracleerbosentanActelion Pharmaceuticals US, Inc.NDACurrent
66215-103TracleerbosentanActelion Pharmaceuticals US, Inc.NDACurrent
66215-103TracleerbosentanActelion Pharmaceuticals US, Inc.NDACurrent
66215-103TracleerbosentanActelion Pharmaceuticals US, Inc.NDACurrent
66215-232TracleerbosentanActelion Pharmaceuticals US, Inc.NDACurrent
66215-232TracleerbosentanActelion Pharmaceuticals US, Inc.NDACurrent
66215-232TracleerbosentanActelion Pharmaceuticals US, Inc.NDACurrent
66215-232TracleerbosentanActelion Pharmaceuticals US, Inc.NDACurrent

Documents#

Document, Submission type, Date table
DocumentSubmission typeDate
85269SUPPL 2026-03-04
84135SUPPL 2025-11-12
84136SUPPL 2025-11-10
84084SUPPL 2025-11-06
83013SUPPL 2025-08-01
79654SUPPL 2024-09-19
77458SUPPL 2024-02-09
77430SUPPL 2024-02-09
76401ORIG 2023-11-06
72573SUPPL2022-11-07
72538SUPPL2022-11-02
70935SUPPL2022-05-03
58799SUPPL2019-05-20
58798SUPPL2019-05-20
58771SUPPL2019-05-17
58508SUPPL2019-05-01
58479SUPPL2019-04-30
56183SUPPL2018-10-30
56110SUPPL2018-10-26
55866ORIG2018-10-10
55865SUPPL2018-10-10
49667ORIG2018-06-25
50142SUPPL2017-12-29